Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising

The path ahead for UNITY Biotechnology, Inc.’s UBX1325 in patients with wet age-related macular degeneration (AMD) has become less straightforward as the company announced that its Phase II study did not show non-inferiority to Regeneron Pharmaceuticals, Inc.’s Eylea (aflibercept). Consequently, there is greater hope among analysts for Unity’s diabetic macular edema (DME) program, particularly the Phase II BEHOLD clinical trial of UBX1325, a program that has shown stronger data to date.

Unity announced results from Part A of the Phase II ENVISION trial in AMD on 27 March, saying that UBX1325 administered as a monotherapy did not achieve non-inferiority compared with...